Serum EPO levels were insufficient for the grade of anemia (mean of serum EPO 42.1 ± 31.8 U/l prior to the treatment) and there was a statistically nonsignificant decrease of serum EPO at the end of the therapy compared to baseline EPO levels (p = 0.09). The gene discussed is EPO; the disease is anemia (phenotype).